SONAR (2019) — Trial Summary

SONAR (2019): Double-blind, randomized, placebo-controlled trial of atrasentan versus placebo in adults with type 2 diabetes and CKD who completed an enrichment period showing albuminuria reduction without excess fluid retention (NCT01858532). Primary composite: doubling of serum creatinine or end-s

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.